Journal
CANCER LETTERS
Volume 340, Issue 1, Pages 113-123Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2013.07.009
Keywords
Pancreatic cancer; Cancer stem cells; Oct4; Nanog
Categories
Funding
- National Natural Science Foundation of China [81101615]
- China Postdoctoral Science Foundation [2012M521107]
- Natural Science Foundation of Jiangsu province [BK2010276]
- University Natural Science Foundation of Jiangsu Province [11KJB320009]
- Natural Science Program of Nantong University [10Z062, 12ZY038]
Ask authors/readers for more resources
Pancreatic cancer is notorious for its difficult diagnosis at early stage and poor recurrence-free prognosis. This study aimed to investigate the possible involvement of Oct4 and Nanog in pancreatic cancer. The high expressions of Oct4 and Nanog in human pancreatic cancer tissues were found to indicate a worse prognostic value of patients. The pancreatic cancer stem cells (PCSCs) that isolated from PANC-1 cell line by flow cytometry exhibited high expressions of Oct4 and Nanog. To investigate whether Oct4 and Nanog play crucial role in maintaining the stemness of PCSCs, double knockdown of Oct4 and Nanog demonstrated that Oct4 and Nanog significantly reduced proliferation, migration, invasion, chemoresistance, and tumorigenesis of PCSCs in vitro and in vivo. The altered expression of the genes related to pancreatic carcinogenesis, metastasis, drug resistance and epithelial-mesenchymal transdifferentiation (EMT) might affect the biological characteristics of PCSCs. Our results suggest that Oct4 and Nanog may serve as a potential marker of prognosis and a novel target of therapy for pancreatic cancer. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available